Buprenorphine 2 mg, 8 mg sublingual tablets
Product Description
SMB Laboratories SA
-
BE -
2015On CPHI since
Company types
Categories
Specifications
SMB Laboratories SA
-
BE
-
2015On CPHI since
Company types
More Products from SMB Laboratories SA (2)
-
Product Buprenorphine + Naloxone 8/2mg, 2/0.5mg sublingual tablets (FDC)
Intro
Dossier:
Indication:
Formulation: -
Product Budesonide+Salmeterol DPI - 240/20µg or 120/20µg FDC
Intro
Dossier:
Indication:
Formulation:
Innovative Fixed Dose Combination of Budesonide and Salmeterol at in two dosages : 240/20µg and 120/20µg (delivered dose) as dry powder for inhalation.Dossier : CTD
Indication: Regular treatment of asthma where use of a combination (i...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance